Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT00961220 Completed - Clinical trials for Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma

Start date: February 1, 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of carmustine when given together with O6-benzylguanine and to see how well they work in treating patients with stage IA-IIA cutaneous T-cell lymphoma. Drugs used in chemotherapy, such as carmustine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. O6-benzylguanine may help carmustine work better by making cancer cells more sensitive to the drug. Giving O6-benzylguanine with carmustine may kill more cancer cells.

NCT ID: NCT00960050 Active, not recruiting - Lymphoma Clinical Trials

Methemoglobinemia in Patients With Childhood Hematologic Cancer or Aplastic Anemia Treated With Dapsone

Start date: June 2009
Phase: Phase 1
Study type: Observational

RATIONALE: Gathering information about patients with childhood hematologic cancer or aplastic anemia treated with dapsone may help doctors learn more about risk factors for developing methemoglobinemia. PURPOSE: This phase I trial is studying methemoglobinemia in patients with childhood hematologic cancer or aplastic anemia treated with dapsone.

NCT ID: NCT00959686 Completed - T-cell Lymphoma Clinical Trials

Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma

BENTLY
Start date: September 2009
Phase: Phase 2
Study type: Interventional

A Phase II clinical study to determine the efficacy of single agent Bendamustine for T cell lymphoma "BENTLY".

NCT ID: NCT00958854 Recruiting - Lymphoma Clinical Trials

Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma

Start date: January 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Thalidomide may stop the growth of lymphoma by blocking blood flow to the cancer. Giving fludarabine and cyclophosphamide together with thalidomide may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving fludarabine and cyclophosphamide together with thalidomide works in treating patients with angioimmunoblastic T-cell lymphoma.

NCT ID: NCT00958256 Completed - Lymphoma Clinical Trials

Study of Bortezomib in Combination With Cyclophosphamide and Rituximab

Start date: August 2009
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if bortezomib when given in combination with cyclophosphamide and rituximab can help to control mantle cell lymphoma. The safety of this drug combination will also continue to be studied.

NCT ID: NCT00958074 Terminated - Clinical trials for Cutaneous T-cell Lymphoma Stage I

Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma

Start date: July 2009
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well vorinostat works in treating patients with primary cutaneous T-cell lymphoma. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth

NCT ID: NCT00956475 Completed - Pain Clinical Trials

Quality of Life in Younger Leukemia and Lymphoma Survivors

Start date: October 2008
Phase: Phase 1
Study type: Observational

RATIONALE: Collecting information about the effect of hematologic cancer and its treatment on quality of life may help doctors learn more about the disease and plan the best treatment. PURPOSE: This phase I trial is studying quality of life in younger leukemia and lymphoma survivors.

NCT ID: NCT00955786 Completed - Lymphoma Clinical Trials

Dose-escalation Study of CX-3543 in Patients With Advanced Solid Tumors or Lymphomas

Start date: July 2005
Phase: Phase 1
Study type: Interventional

This phase 1 study of CX-3543 is designed to test the safety, tolerability and highest safe dose level of this drug in patients with advanced solid tumor cancers.

NCT ID: NCT00955292 Terminated - Lymphoma Clinical Trials

Dose-escalation Study of Quarfloxin in Patients With Advanced Solid Tumors or Lymphomas

Start date: July 2007
Phase: Phase 1
Study type: Interventional

This phase 1 study of quarfloxin (CX-3543) is designed to test the safety, tolerability, and highest safe dose of this drug when administered intravenously weekly for three weeks of a four week cycle in patients with advanced solid tumors.

NCT ID: NCT00954005 Terminated - Indolent Lymphoma Clinical Trials

Study With Rituximab-Gemcitabine/Oxaliplatin in Relapsed Indolent Lymphoma

R-GO
Start date: January 2003
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the phase I part is to determine the tolerability, the initial safety profile and maximum tolerated dose of oxaliplatin in combination with gemcitabine for indolent lymphoma. In the phase II part the investigators want to estimate the activity of gemcitabine and oxaliplatin in combination with rituximab for patients with relapsed/refractory indolent lymphoma.